Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
AerCap is using tight aircraft supply to produce record earnings, asset-sale gains and buybacks. The upside is real, but the model still runs on leverage, airline customer health and aircraft residual values.
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenRocket Lab reported FY2025 revenue of $601.8 million, Q1 2026 revenue of $200.3 million, a FY2025 net loss of $198.2 million and $1.2 billion of cash. The thesis depends on launch cadence, space systems demand, Neutron investment, operating leverage, cash burn
OpenBoeing is a globally strategic aerospace franchise with FY2025 revenue of $89.5 billion and Q1 2026 revenue of $22.2 billion, but the investment case still turns on production discipline, safety oversight, defense charges and recurring cash generation.
Open20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAeroméxico has premium demand, loyalty scale and record-margin evidence after its U.S. listing, but the Delta JCA, MEX constraints, fuel, FX, engine issues and a negative equity balance sheet make the setup high risk.
OpenAdvanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.
OpenAdagene is trying to turn SAFEbody antibody masking into a broader immuno-oncology platform. The hook is muzastotug's early dose-dependent signal; the catch is that randomized proof, partner execution, and financing still decide the stock.
OpenActuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenArcher has enough liquidity to make the eVTOL race worth watching, but the filings still show a pre-revenue aircraft company burning cash while certification, manufacturing, launch operations, conditional orders, and IP fights decide whether Midnight becomes a
OpenOfficial-source baseline for Ascentage Pharma using SEC submissions, FY2025 Form 20-F, SEC companyfacts, company-filed FY2025 results releases, ASCO 2026 update, annual meeting materials, and oncology peer filings.
OpenAgilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
Open